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Objectives. To find potential diagnostic markers or therapeutic targets, we used differential display technique to 
identify genes that are over or under expressed in human ovarian cancer. 
Methods. Genes were initially identified by differential display between two human ovarian surface epithelium 
cultures and two ovarian cancer cell lines, A2780 and Caov-3. Genes were validated by relative quantitative 
RT-PCR and RNA in situ hybridization.  
Results. Twenty-eight non-redundant sequences were expressed differentially in the normal ovarian epithelium 
and ovarian cancer cell lines. Seven of the 28 sequences showed differential expression between normal ovary 
and ovarian cancer tissue by RT-PCR. USP36 was over-expressed in ovarian cancer cell lines and tissues by 
RT-PCR and RNA in situ hybridization. Northern blot analysis and RT-PCR revealed two transcripts for USP36 in 
ovarian tissue. The major transcript was more specific for ovarian cancer and was detected by RT-PCR in 9/9 
ovarian cancer tissues, 3/3 cancerous ascites, 5/14 (36%) sera from patients with ovarian cancer, and 0/7 sera 
from women without ovarian cancer.  
Conclusion.  USP36 is overexpressed in ovarian cancer compared to normal ovary and its transcripts were 
identified in ascites and serum of ovarian cancer patients. 
Key words: ovarian cancer; biological markers; ubiquitin specific peptidase 36 (USP36); deubiquitinating enzyme 
Introduction 
Ovarian cancer, the most fatal gynecological 
cancer, is ranked fourth in overall cancer mortality 
among women in the United States, causing ~16,000 
deaths per year [1]. A woman’s estimated risk of 
developing ovarian cancer in her lifetime is 1 in 70 or 
1.4%. Unfortunately, no fully effective mass screening 
method for early ovarian cancer has yet been 
developed. The currently available methods, such as 
abdominal and transvaginal ultrasonography, color 
flow Doppler, and CA-125, are not specific enough for 
detecting early, treatable ovarian cancer through 
population screening [2]. Therefore, the disease is 
detected at an advanced stage in most patients, being 
confined to the ovaries at diagnosis in fewer than 30% 
of cases. 
Epithelial ovarian cancer develops from a clone of 
cells [3], which suggests that early stages of the disease 
could be detected if specific tumor markers expressed 
at early stages could be identified. To find potential 
diagnostic markers for early ovarian cancer, we used 
differential display previously described [4] for 
identifying key genes that were uniquely 
overexpressed or silenced in ovarian cancer compared 
with normal cells. As more than 85% of human ovarian 
cancers are thought to be derived from ovarian surface 
epithelium (OSE) [5], we performed differential 
display to compare gene expression patterns in two 
cultured OSE cells and two human ovarian cancer cell 
lines, A2780 and Caov-3. We used relative quantitative 
RT-PCR and RNA in situ hybridization techniques to 
further evaluate the differentially expressed genes. 
USP36 was confirmed over-expressed in ovarian 
cancer cell lines and tissues. The USP36 predominant 
transcript was further characterized in multiple 
human tissues, cancerous ascites, and sera from 
women with and without ovarian cancer. 
In eukaryotic cells, ubiquitination and Int. J. Med. Sci. 2008, 5 
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deubiquitination regulate a number of biological 
processes by balancing cellular protein degradation. 
This post-translational modification is a dynamic and 
reversible process controlled by the coordinate action 
of multiple ubiquitin-conjugating and 
deubiquitylating enzymes. USP36 is one of the 
deubiquitinating (DUB) enzymes and belongs to 
ubiquitin-specific processing proteases (USP). USP 
removes ubiquitin from specific protein substrates and 
allow protein salvage from proteasome degradation, 
regulation of protein localization or activation [6]. 
Previous studies demonstrated that USP36 has DUB 
activity both in vivo and in vitro [7, 8]. 
Materials and methods 
Cell cultures and tissue samples 
Tissue samples from normal ovaries and ovarian 
cancers were obtained from women undergoing 
oophorectomies. RNA from other human tissues was 
obtained from the Tissue Procurement Core at the 
Siteman Cancer Center. The study was approved by 
the Human Studies Committee of Washington 
University in St. Louis.   
Human OSE cells were collected according to the 
method described by Kruk et al [9] and cultures were 
maintained in a mixture of Medium 199 with Earle’s 
balanced salt solution (Sigma, St. Louis, MO) and 
MCDB105 (Sigma, St. Louis, MO) (1:1, pH 7.3) 
supplemented with 15% FBS (medium 199/105/15% 
FBS) and 2 mM L-glutamine. The medium contained 
103 IU/ml of penicillin and 103 μg/ml of streptomycin 
and fungizone (250 ng/ml) for the first week. Cells 
were plated onto a T25 polystyrene flask with 5 ml of 
medium and incubated undisturbed at 37°C in 5% 
CO2/air for 48 hours. The old medium, which 
contained blood and debris, was replaced with fresh 
prewarmed (37°C) medium. Subsequently, the culture 
medium was changed every 3-4 days as needed. When 
the culture was confluent, the cells were subcultured 
with trypsin/EDTA (Life Technologies, Gaithersburg, 
MD). 
To characterize the cultured cells, we added 3-4 
drops (50-100 μl) of prewarmed medium into each well 
of a microscope slide well chamber (16 wells/slide). 
Two drops of trypsin/EDTA/cell mixture were seeded 
into each well. The medium was changed every 3-4 
days until the cells were confluent. Then cells were 
fixed in methanol/acetone and stained for cytokeratin 
and vimentin using anti-cytokeratin AE1/AE3 
(Boehringer Mannheim, Indianapolis, IN) and 
anti-vimentin (Boehringer Mannheim, Indianapolis, 
IN) following the manufacturer’s instructions. 
To propagate the cells and extract their RNA, we 
placed the remaining trypsin/EDTA/cell mixture in a 
T75 polystyrene flask and added 10 ml of prewarmed 
(37°C) medium. The medium was changed on the next 
day to remove debris and then changed every 3-4 days. 
When the cells in the flask were confluent, they were 
trypsinized and RNA was extracted. 
The A2780 cell line was cultured in RPMI 1640 
medium. The Caov-3 cell line was cultured in 
Dulbecco's modified Eagle's medium (DMEM). Both 
media were supplemented with 10% FBS, 2 mM 
L-glutamine, 103 IU/ml of penicillin and 103 μg/ml of 
streptomycin. The cell lines were cultured in 5% CO2 at 
37°C. 
Differential display 
Total cellular RNA was isolated from the cell 
lines by the guanidinium isothiocyanate method [10]. 
Contaminating DNA was removed with the 
MessageCleanTM Kit (GenHunter Co., Nashville, TN). 
Differential display technique was first described by 
Liang and Pardee in 1992[4]. Since then the technique 
has been applied in numerous studies. We 
performanced the differential display using the 
RNAimageTM kit (GenHunter Co. Nashville, TN), 
following the manufacturer’s instructions. 
Total RNA was reverse transcribed using the 
primer H-T11A (5'-AAGCTTTTTTTTTTTA-3'), 
H-T11G (5'-AAGCTTTTTTTTTTTG-3'), or H-T11C 
(5'-AAGCTTTTTTTTTTTC-3'). The product was 
amplified by PCR using one of the primer pairs labeled 
with alpha-[35S]-dATP. Overall, 24 primer pairs were 
used for PCR, including combinations of each of the 
above three primers with  
H-AP49 (5'-AAGCTTTAGTCCA-3'),  
H-AP50 (5'-AAGCTTTGAGACT-3'),   
H-AP51 (5'-AAGCTTCGAAATG-3'),   
H-AP52 (5'-AAGCTTGACCTTT-3'),  
H-AP53 (5'-AAGCTTCCTCTAT-3'),   
H-AP54 (5'-AAGCTTTTGAGGT-3'),  
H-AP55 (5'-AAGCTTACGTTAG-3'), or  
H-AP56 (5'-AAGCTTATGAAGG-3').   
All PCR products were electrophoresed in parallel on 
extended-format denaturing 6% polyacrylamide gel 
and displayed by autoradiography. 
cDNA cloning and sequencing 
PCR products of the RNAs that were found to be 
differentially expressed between OSE cell lines and 
ovarian cancer cell lines were cut out from a 
polyacrylamide gel, re-amplified with the same primer 
pair, purified on agarose gels using the QIAquick Gel 
Extraction Kit (QIAGEN, Valencia, CA), and then 
cloned into the pCR-TRAP Cloning SystemTM 
(GenHunter Co., Nashville, TN). The inserts of clones 
were sequenced using either the Lgh and or Rgh 
primer flanking the cloning site. All sequencing Int. J. Med. Sci. 2008, 5 
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reactions were performed ustilizing ABI PRISMTM 
BigDyeTM Terminator Cycle Sequencing Ready 
Reaction Kit (Perkin Elmer, Foster City, CA).  
RT-PCR 
Relative quantitative RT-PCR was performed 
according to the method of Nicoletti and Sassy-Prigent 
[11], with some modification. RNA samples were 
diluted to 1 μg/4 μl (assessed by OD260). One μg of 
each mixed RNA (normal and cancer) sample was 
used for reverse transcription in a reaction mixture 
whose final volume was 20 μl. The mixture contained 1 
μg of oligo(dT)15, 200 U of MMLV reverse 
transcriptase, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 
mM MgCl2, 10 mM dithiothreitol (DTT), 20 U RNase 
inhibitor (Promega, Madison, WI), and 0.5 mM each of 
dNTP and 0.1% DEPC (Sigma, St. Louis, MO). It was 
incubated at 37°C for 60 min. 
The primers were designed using the Primer 3 
program (http://www.genome.wi.mit.edu/cgi-bin/ 
primer/primer3_www.cgi). Multiplex PCR was 
performed in a total volume of 20 μl that contained 0.5 
μM of each primer, 500 μM each of dNTP, 10 mM 
Tris-HCl (pH 8.3), 50 mM KCl, 6 mM MgCl2 and 2.5 U 
of AmpliTaq DNA Polymerase (Perkin-Elmer, 
Norwalk, CT). An endogenous housekeeper gene, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was 
used as an internal standard to correct for tube-to-tube 
variations in amplification efficiency. The PCR 
thermocycles were: 4 min at 94°C, (1.5 min at 94°C, 2 
min at 55°C, and 3 min at 72°C)20, and 10 min at 72°C. 
A minus RT-PCR reaction was included for every RNA 
sample to confirm the absence of contaminating DNA. 
Quantitative data on the PCR products were 
acquired by digitizing photographs of ethidium 
bromide-stained agarose gel into gray-scale images 
using the public NIH Image 1.71 program and by the 
Wave DNA Fragment Analysis System 
(Transgenomic, Omaha, NE). 
RNA in situ hybridization 
RNA in situ hybridization was performed using a 
digoxigenin (DIG) labeled riboprobe. Sense and 
antisense riboprobes were synthesized separately and 
labeled in total volume of 20 µl. The reaction mixture 
contained 1 x transcription buffer, 1 x DIG RNA 
labeling mixture from the DIG Genius 4 RNA Labeling 
Kit (Boehringer Mannheim, Indianapolis, IN), 5 mM 
DTT, 20 U of RNase inhibitor (Promega, Madison, WI), 
40 U of T7 or SP6 RNA polymerase (Promega, 
Madison, WI), and 60 ng of linearized DNA templates. 
The templates were generated from the PCR products 
amplified using T7 and SP6 primer (GenHunter Co., 
Nashville, TN) from IMAGE clone 2400019. The 
generated antisense probe for USP36 is 267bp (5’- 
ggatccatttaggtgacactatagaagtacctgaaaggaagcttttttttttcg
aggatttcctgtatttattaagttacaagttggcaggcacagcttgagcaacat
agaaaagtaatcttcttgagttatacaatcatttaaattccaaagcactcacaa
aattgagcaaacaaagccactatttgcatatttgggaaaggaaacatattgct
aacgtaagcttcctgaatccttcatggcctatagtgagtcgtattagaattc-3’
). The synthesized riboprobe was precipitated by 
ethanol and verified by RNA electrophoresis. 
Formalin-fixed paraffin-embedded tissue slides were 
deparaffinized in Hemo-De (Fisher Scientific, 
Pittsburgh, PA), rehydrated in serially diluted ethanol 
(100%, 95%, 70%, 50%, and 30%), digested in 2 µg/ml 
proteinase K at 37ºC for 30 min, and then rinsed 3 
times in PBT (PBS containing 0.1% Tween 20 and 0.1% 
DEPC). The pretreated slides were hybridized at 55ºC 
overnight in a buffer containing 50% formamide, 5 x 
SSC, 100 µg/ml Salmon Sperm DNA, 100 µg/ml 
heparin, 0.1% Tween 20, 1 x Denhardt’s medium, 0.1% 
CHAPS, 5 mM EDTA, and ~16 µg/ml DIG-labeled 
riboprobe. After the slides were rinsed with 0.1 x SSC 
and blocked with blocking buffer (5% sheep serum, 2 
mg/ml BSA, and 1% DMSO in PBT), DIG-labeled 
riboprobe was detected with anti-digoxigenin-AP, Fab 
fragments (Boehringer Mannheim, Indianapolis, IN), 
according to manufacture’s instructions.  
Northern blot 
mRNA was extracted by the Messenger RNA 
standard isolation kit (Sigma, St. Louis, MO), and total 
RNA was extracted by the ToTALLY RNA kit 
(Ambion, Austin, TX). The products were 
electrophoresed on 1.5% formaldehyde/1% agarose 
gel with RNA MilenniumTM S i z e  M a r k e r  ( A m b i o n ,  
Austin, TX). The RNA was transferred from the gel to 
BrightStar-PlusTM Membranes (Ambion, Austin, TX) 
and cross-linked onto the membrane with UV. 
Single-strand DNA probes labeled with 32P dCTP were 
made by asymmetric PCR, using antisense primer and 
same template as in RNA in situ hybridization. The 
synthesized probe was purified on a centrifuge 
column, and its specific activity was measured by 
liquid scintillation analysis. The probe for USP36 is 
130bp (5’- ttacaagttggcaggcacagcttgagcaacatagaaaagt 
aatcttcttgagttatacaatcatttaaattccaaagcactcacaaaattgagca
aacaaagccactatttgcatatttgggaaaggaaa-3’). The 
membrane was hybridized in buffer containing 1.6 x 
107 cpm/ml probe and 6.0 x 104 cpm RNA 
MilenniumTM Size Marker (Ambion, Austin TX) at 
50ºC for 16 h. The membrane was rinsed with low 
stringency solution 2 x SSC and 0.1% SDS at 50ºC for 15 
min and then autoradiographed at -70°C with 
intensifier screen. 
Isolation of RNA from ascites and serum 
Serum was isolated and stored at -70°C until 
processed. Ascites was collected at surgery and Int. J. Med. Sci. 2008, 5 
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centrifuged at 4°C for 5 minutes at 150g. The 
supernatant was removed and stored at -70°C until 
processed. Isolation of RNA was preformed using 
TRIzol® LS Reagent (Invitrogen Corporation, 
Carlsbad, CA) or magnetic bead method - Ambion’s 
MagMaxTM technology (Ambion, Inc., Austin, TX) 
following manufactures’ protocol. DNA and RNA 
input levels ranging from 20 copies to 25x106 copies 
can be quantitatively recovered from plasma, serum, 
and milk (MagMaxTM manual). The concentration and 
purity of RNA were determined by using the 
Nanodrop® ND-1000A UV-Vis Spectrophotometer 
(NanoDrop Technologies, Wilmington, DE) and 
Agilent 2100 Bioanalyzer (Agilent Technologies, Inc. 
Santa Clara, CA). The concentration of RNA extracted 
from the sera range from 0.2 ~ 26ng/ul, which is 
similar with the results from a recent study [12]. RNA 
was processed for cDNA using Ambion 
RETROscript® Kit (Ambion, Inc.Austin,TX). An 
internal standard, RPS14, was used to confirm the 
RNA quality suitable for RT-PCR. 
Results 
Human OSE cell lines 
Cultures of OSE cells were characterized by 
immunostaining  with monoclonal antibodies, 
anti-keratin AE1/AE3 and anti-vimentin. The 
anti-keratin AE1/AE3 monoclonal antibody 
specifically recognizes human epithelial cytokeratin, 
an intermediate filament in epithelial cells that is 
absent from mesenchymal cells such as fibroblasts and 
smooth muscle cells. The anti-vimentin monoclonal 
antibody was used to stain cells of mesenchymal 
origin, including endothelial cells, vascular smooth 
muscle cells, connective tissue cells, and all types of 
blood cells. Immunostaining with both antibodies 
confirmed the epithelial origin of 6 human OSE cell 
cultures and 2 cell lines (N 1/4 and N 1/29) were used 
for the differential display.  
Genes expressed differentially between human OSE 
cells and ovarian cancer cell lines 
Thirty-one bands were differentially expressed 
between the 2 human OSE cell lines and 2 ovarian 
cancer cell lines (A2780 and Caov-3). Among those 31 
bands, 15 were significantly overexpressed in the two 
ovarian cancer cell lines compared with the two 
normal OSE cell lines and 16 were expressed at lower 
levels in the two ovarian cancer cell lines than in the 
two OSE cell lines. Figure 1 provides an example of 
differential expression.  
 
 
Figure 1    Differential display of human OSE cells and 
ovarian cancer cell lines. Each vertical panel represents one 
primer pair, and every primer pair includes 4 different cell lines: 
N1 (N1/4), N2 (N1/29), C1 (A2780), and C2 (Coav-3). The left 
panel shows bands that are expressed at a higher level in the 
normal human OSE cell lines N1/4 and N1/29 (bands A, B, C, 
and D) than in the cancer cell lines. The right panel shows the 
bands that are overexpressed in the human ovarian cancer cell 
lines A2780 and Coav-3 (bands E, F, and G). G1 and G2 are 
different bands with identical sequences.  
 
We cloned all 31 differentially expressed bands 
into pCR-TRAP vectors. The clones were screened 
according to the size of the inserts, using PCR and the 
primer pair that flanked the cloning site of the 
pCR-TRAP vector and then sequenced. For two bands, 
two different sequences with similar sizes were 
identified. Therefore, a total of 33 different cloned 
sequences were obtained. 
To identify these sequences, we used the blastn 
algorithm to query three nucleotide sequence 
databases on the NCBI website 
(http://www.ncbi.nlm.nih.gov): nr (non-redundant), 
dbEST, and dbSTS. The 33 clones represented 28 
nonredundant sequences. Fourteen were 
underexpressed in both cancer cells lines and 14 were 
overexpressed in both cancer cell lines. Among the 28 
nonredundant sequences, 22 matched known genes or 
EST, rest of them either matched to genomic DNA that 
contained no known EST or intron of known gene 
(Table 1).   
Validation of differential expression in human ovarian 
tissues 
To confirm that the 28 non-redundant sequences 
were expressed differentially in the normal human 
ovary and ovarian cancer tissues, we performed 
relative quantitative RT-PCR, using four normal 
human ovary tissue samples (NO1, NO2, NO3, and 
NO4) and four human ovarian cancer tissue samples 
(OC1, OC2, OC3 and OC4). To obtain a relative 
quantitative measurement of the gene expression, an 
alternative quantitative PCR method was used [11]. 
First, a series of 5 progressive dilutions achieved by 
mixing RNAs of tumor (T) and matched normal (N) Int. J. Med. Sci. 2008, 5 
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samples (T4/N0, T3/N1, T2/N2, T1/N3 and T0/N4) 
were assembly. Then an aliquot of each dilution mix 
was submitted to a standard RT-PCR. After PCR, the 
photographs of ethidium of bromide-stained gels were 
digitized into gray-scale images. The amount of 
nucleic acids was determined by densitometry. The 
amount of nucleic acid was proportional to the log of 
the optic density. The sum of the logarithms of the 
pixel values was used to estimate the amount of 
nucleic acid in a band. The fold increase was compared 
based on the expression of normal sample (T0/N4). 
The internal control of GAPDH was used to correct for 
tube-to-tube variations in initial sample inputting. In 
addition, we did the semi-quantitative RT-PCR using 
minimal cycling to avoid the artificial effect of 
saturation of PCR products. Seven of the 28 sequences 
showed differential expression between the normal 
and cancer tissues by relative quantitative RT-PCR 
(Table 2 and 3). 
Table 1. Genes (EST) identified in this study. 
Clone    Band *  Tissue over expressed  UniGene ID  Gene  Chromosome Location 
a & b-1    Normal  N/A  OK/SW-cl.16   1p36.33 
b-2   Normal  Hs.471234  CCNYL1  2q33.3  
2   Normal  Hs.592304   ERO1L  14q22.1 
3   Normal  Hs.348319   Transcribed locus  Chr. 10 
11 A  Normal  Hs.  40098  GREM1  15q13-q15 
12   Normal  Hs.369920  RAP1B  12q14 
13   Normal  N/A**  Genomic  sequence   
14   Normal  Hs.655420  AMDHD2  16p13.3 
15   Normal  Hs.459790  VPS13A  9q21 
16   Normal  Hs.210469  ELMO2  20q13 
17 & 20 & 34    Normal  Hs.380953  RPL38  17q23-q25 
17 & 20 & 34   B  Normal Hs.713533  LTBP1  2p22-p21 
18   Normal  Hs.370140   HELZ  17q24.2 
21 C  Normal  Hs.75813  PKD1  16p13.3 
23 D  Normal  Hs.190028  GSTO1  10q25.1 
4   Cancer  N/A  Genomic  sequence   
10   Cancer  N/A  Genomic  sequence   
19 E  Cancer  Hs.75277  RMND5A  2p11.2 
22   Cancer  Hs.75527  ADSL  22q13.2 
24   Cancer  Hs.107474  Transcribed locus  Chr. 2 
25   Cancer  Hs.486095  PDSS2  6q21 
26-1   Cancer  N/A  Genomic  sequence   
26-2 F  Cancer  Hs.464243  USP36  17q25.3 
27 & 28  G  Cancer  Hs.460298  POLR3E  16p12.1 
29 & 32    Cancer  Hs.22857  CHORDC1  11q14.3 
30   Cancer  N/A  Genomic  sequence   
31   Cancer  N/A  Genomic  sequence   
35   Cancer  Hs.184233  HSPA9  5q31.1 
36-1   Cancer  Hs.656195  C21orf51  21q22.12 
*Band: differentially expressed genes, which validated by RT-PCR (Table 2 and Table3), in normal or tumor ovary cell lines. 
**N/A: not available 
Table 2.  Genes identified by differential display (increased in normal ovary or ovarian cancer) and validated by RT-PCR. 
Band  Tissue over expressed  Chromosome Location  Gene 
Symbol 
GeneID Gene name 
A Normal  15q13-q15  GREM1  26585  gremlin 1, cysteine knot superfamily, homolog 
(Xenopus laevis) 
B Normal  2p22-p21 LTBP1  4052  latent transforming growth factor beta binding 
protein 1 
C Normal  16p13.3  PKD1  5310  polycystic kidney disease 1 (autosomal 
dominant) 
D Normal  10q25.1  GSTO1  9446  glutathione S-transferase omega 1 
E Cancer  2p11.2  RMND5A  64795  required for meiotic nuclear division 5 homolog 
A (S. cerevisiae) 
F Cancer  17q25.3 USP36  57602  ubiquitin specific peptidase 36 
G Cancer  16p12.1  POLR3E  55718  polymerase (RNA) III (DNA directed) 
polypeptide E (80kD) 
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Table 3. Relative expression levels of the seven genes in four normal human ovary tissues and four human ovarian cancer tissues. 
Band  Gene  NO1  NO2  NO3  NO4  OC1 OC2 OC3  OC4 
A  GREM1  ND + ++++  +  ND  -  -  - 
B  LTBP 1  + -  +  ++  -  -  -  - 
C  PKD1  - ++  - ++  -  -  -  - 
D  GSTO1  + +  - +  -  -  -  - 
E  RMND5A  -  -  -  -  + + +  + 
F  USP36  -  -  -  -  ++++ - ++++ ++ 
G  POLR3E  - -  ND  -  -  +++  ND  +++ 
ND: No data;  
-: no increase or increase < 2 times;  
+: Increased 2~10 times; ++: Increased 10~100 times; +++: Increased 100~1000 times; ++++: Increased more than 1000 times;  
NO = normal ovary, OC = ovarian cancer 
 
The three over-expressed sequences in ovarian 
cancer tissue confirmed by RT-PCR were USP36, 
RMND5A, and POLR3E. We further evaluated the 
expression of these 3 genes by RNA in situ 
hybridization, using nine ovarian cancer tissues 
(including endometroid adenocarcinoma, serous 
adenocarcinoma, borderline serous tumor, papillary 
serous adenocarcinoma, clear cell adenocarcinoma, 
and mixed epithelial type adenocarcinoma) and eight 
matched normal ovaries or fallopian tubes from the 
same patients. A sense probe was used as the negative 
control. For USP36, all nine ovarian cancer tissues gave 
a strong positive signal (Figure 2, panels A-D) and 
eight normal tissues gave very weak or negative 
results in the surface epithelium, stroma, and follicles 
(Figure 2, panels E and F). For RMND5A, six of the 
nine ovarian cancer tissues were positive and all the 
normal tissues were weak or negative. For POLR3E, 
four of the nine ovarian cancer tissues gave positive 
results and all the normal tissues showed weak or 
negative staining.  
 
Figure 2 RNA  in situ hybridization of USP36. A and B show 
a well-differentiated endometrioid adenocarcinoma hybridized 
with antisense (A) and sense (B) riboprobe. C and D show a 
poorly differentiated carcinoma of mixed epithelial origin, 
endometrioid, and papillary serous hybridized with antisense 
(C) and sense (D) riboprobe. E and F are from normal ovary 
hybridized with antisense (E) and sense (F) riboprobe.  
 
The predominant transcripts of USP36 and RMND5A 
in ovarian cancer cell lines 
Northern blot analysis revealed two transcripts 
for  USP36, ~6.0 kb (major transcript) and ~4.7 kb 
(minor transcript) (Figure 3). USP36 locates on 
chromosome 17q25.3 and covers 44571 bp genomic 
sequences. Seventeen mRNAs and 482 EST sequences 
represent human USP36 in NCBI UniGene database 
(http://www.ncbi.nlm.nih.gov/UniGene). The ESTs 
come from almost every tissue, including ovary and 
cervix. The sequence alignment between 
representative mRNA and the genomic sequence 
indicates that these mRNAs are spliced transcript 
variants of the USP36 gene (Figure 4). Among these 
mRNAs, AB040886 (NM_025090, 5879 bp) and 
AK022840 (4650 bp) most closely match the major and 
minor transcripts seen in the Northern blot (Figure 3). 
The sequence from the differential display band F 
(Table 2 and 3) perfectly matches both mRNAs, but 
only the AK022840 transcript contained the 
homologous 3’ end identified by initial differential 
display (Figure 4). Int. J. Med. Sci. 2008, 5 
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Figure 3  Northern blot. Lanes A and C are RNA Size 
Marker; lanes B and D are mRNAs (10 µg polyA RNA in each 
lane) from the A2780 cell line. The first panel is USP36 and the 
second panel is RMND5A. 
 
To confirm which transcripts are expressed in 
ovarian cancer, we designed 6 RT-PCR primers that 
detect specific mRNAs (Table 4, Figure 4). All primer 
pairs except USP36-2 were designed to cross an intron 
to eliminate interference by any contaminating 
genomic DNA. RT-PCR results demonstrated the 
expression of AB040886 (~ 6 kb) and AK022840 (~4 kb) 
in ovarian cancer cell lines (Figure 5) and were 
consistent with the Northern blot results. AB040886 
has 21 exons, encodes a protein with 1121 amino acid 
(aa) and contains one ubiquitin carboxyl-terminal 
hydrolase (UCH) family 2 motif. AK022840 has 16 
exons and encodes a protein with 726 aa and contains 
part of the ubiquitin carboxyl-terminal hydrolase 
(UCH) domain. 
Northern blot analysis revealed two transcripts 
for RMND5A (~6.0 kb and ~2.5 kb) by using mRNA 
from ovarian cancer cell line A2780 (Figure 3). The 
sequence  RMND5A resides on chromosome 2p11.2 
and covers 57756 bp genomic sequences. Several 
mRNAs corresponding to this gene are documented 
on the NCBI website. Recent study showed that 
RMND5A (p44CTLH) was associated with several 
proteins and composed a large protein complexes. It 
contains LisH/CTLH motifs, which are present in 
proteins involved in microtubule dynamics, cell 
migration, nucleokinesis, and chromosome 
segregation [13]. 
 
Table 4. RT-PCR primer set and target mRNA.  
Primer 
Name 
Forward Primer 
(5’ – 3’) 
Reverse Primer 
(5’ – 3’) 
Target 
mRNA 
mRNA 
(bp) 
PCR 
(bp) 
USP36-1 GTCATCTTGCTGAGCCCTTC  GGCATTCTCTCCACTCAGGA  AK022840  4650  255 
USP36-2 AATTTTGTGCTTGGGAATGG  TTTTTTTCACAGAACCGGAG AK023077  2479  223 
USP36-3 ATGTGGTCCAGGAACTGCTC  CCCACCTCACCCTTACACC  AB040886  5879  359 
USP36-3A ATGACTGGGACGAAGAGTTTGAC  CTACACACATACACGGCACACAC AB040886  5879  247 
USP36-4 GAAAGGAGGTGCAGAGGATG  CTGTGCCTGCCAACTTGTAA  AI963973  423  211 
USP36-5 ACTCTCCCAGACACCCACAC  TGGAACAGTTCGTTTCCTGA AK022913*  3760  247* 
* USP36-5 primer set also detects AK022840 and AB040886 as a 389 bp PCR product.  
 
 
 
 
Figure 4 Transcripts  for  USP36 and primer location. A. Schematic representation of five USP36 transcripts from cDNA clones. 
Tel: telomere end; Cen: centromere end. B. The positions of five primers and band F are indicated schematically. Each RT-PCR 
primer is designed to cross introns (except primer USP36-2) and to detect a specific mRNA transcript. 
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Figure 5  Determination of USP36 transcripts by RT-PCR. 
Column 1-5 represent primers USP36-1 to USP36-5, and 
column M represents a 100 bp DNA ladder. Primers USP36-1 
(AK022840) and USP36-3 (AB040886, NM_025090) were 
positive. Primer pairs USP36-4 (AI963973) and USP36-2 
(AK023077) represent genomic DNA. Primer USP36-5 
(AK022913) detected a 389 bp band which matches AB040886 
and AK022840 but was negative for the 247 bp band specific for 
AK022913 (Figure 4).  
 
Expression pattern of USP36 mRNA transcripts in 
multiple human tissues 
We further evaluated the expression of USP36 
major transcript AB040886 and minor transcript 
AK022840 in multiple human tissues by RT-PCR. 
USP36-3A was developed to identify AB040886 with a 
smaller PCR product in serum and ascites (Table 4). 
The results showed that the major transcript AB040886 
is more specific for ovarian cancer tissue than the 
minor transcript AK022840. AB040886 was detected in 
9/9 human ovarian cancer tissues, 3/3 ascites 
specimens from ovarian cancer patients, and 5/14 
(36%) sera from ovarian cancer patients. Sequencing 
two of five PCR products from sera confirmed the 
result. None of seven sera from women without 
ovarian cancer detected AB040886.  
As comparison to ovarian cancer, 4 normal 
ovaries tissues showed absent expression except one 
hemorrhagic torsed benign ovary had expression 
similar to ovarian cancer. In addition, AB040886 
showed absent expression in normal tissues from 
pancreas, kidney, cervix, spleen, testis, endometrium, 
breast, colon, myometrium, and liver by RT-PCR. 
There was minimal to absent staining in cancers from 
prostate, cervix, colon, lung and breast. AK022840 was 
ubiquitously expressed in all tested tissues. 
Discussion 
To identify overexpressed or silenced genes in 
ovarian cancer, we used differential display to 
compare human ovarian cancer cell lines with human 
normal OSE cell lines. We detected 28 differentially 
expressed genes. When we used RT-PCR and RNA in 
situ hybridization to validate the differential 
expression of these sequences in human normal 
ovarian tissue and ovarian cancers and found that 
USP36 was consistently overexpressed in the ovarian 
cancers tissues evaluated. RNA in situ hybridization 
showed USP36 expression in various histologic types 
of epithelial ovarian cancer. Northern blot and RT-PCR 
identified two transcripts. The major transcript 
AB040886 appears more specific for ovarian cancer 
tissue than the minor transcript AK022840. 
USP36 is a deubiquitinating enzyme, also known 
as ubiquitin specific protease (USP). The 
deubiquitinating enzymes are a component of the 
ubiquitin system, which is important for regulating 
numerous basic biological processes, including 
cell-cycle progression, apoptosis, signal transduction, 
transcriptional regulation, receptor downregulation, 
and endocytosis [14]. Like protein phosphorylation 
and dephosphorylation, protein ubiquitination is a 
dynamic process. It is controlled by the coordinated 
actions of ubiquitin conjugating enzymes and 
deubiquitinating enzymes that respectively add or 
remove the ubiquitin moiety from a target protein. The 
deubiquitinating enzymes are also involved in 
processing of poly-ubiquitin precursors into ubiquitin 
monomers, targeting or salvage of proteasomal 
substrates and regulating nonproteolytic functions of 
mono- and poly-ubiquitination [15, 16]. 
Ubiquitin-mediated proteolysis has been 
implicated in the degradation of several important 
oncogene products, such as N-myc, c-myc, c-fos, c-jun, 
β-catenin, and adenovirus E1A [14]. Aberrations in 
their removal may derail the cell cycle and result in 
malignant transformation. UCH-L1, a 
deubiquitinating enzyme, is highly expressed in 
primary lung cancers and lung cancer cell lines and 
strongly correlates with advanced stage [17, 18]. Yeast 
two-hybrid analysis showed UCH-L1 interacts with 
JAB1, a Jun activation domain binding protein that can 
bind to p27Kip1 [19]. Another deubiquitinating enzyme, 
Unp (USP4) is tumorigenic when overexpressed in 
mice, acting like a proto-oncogene [20]. 
USP36 cloning and enzymatic analysis was 
published by Quesada et al. along with 21 other novel 
human ubiquitin-specific proteases. Northern blot 
analysis showed USP36 to be present in leukocytes, 
ovary, testis, and prostate at about ~ 7.5 kb (probe 
information not provided, there is no size marker to 
indicate the band size) [8]. According to the provided 
protein IDs in the paper, NP_079366 matches USP36. 
The protein is 1123aa and the encoding mRNA is 
NM_025090 (5234bp) (http://www.ncbi.nlm.nih.gov). 
It is exactly the same protein we described in this 
study (AB040886, encoding USP36, 1123aa). Enzymatic Int. J. Med. Sci. 2008, 5 
 
141
assays demonstrated that USP36 had USP activity. 
Kim  et al. identified USP36, called HeLa DUB-1, in 
extracts from HeLa by RT-PCR with a pair of primers 
designed for AK022913 [7, 21]. Although these 
publications stated USP36 was isolated from ovarian 
cancer, HeLa is a cervical cancer cell line [22]. 
According to the published sequence, the HeLa DUB-1 
cDNA  is a different transcript from the major 
transcript (AB040886) of ovarian cancer cell lines 
described in this paper and corresponds to AK022913 
(but with different 3’ and 5’ terminals). Our RT-PCR 
results indicated that AK022913 is not expressed in 
human ovarian cancer cell lines (Figure 5, lane 5). In 
Kim’s paper, they mentioned that USP36 contains 18 
exons. According to the same website 
http://genome.ucsc.edu/ (version March 2006), 
USP36 contain 21 exons, in which 18 of them are 
coding exons. 
Circulating nucleic acids (CNA) was first 
reported in 1940s. In 1977, Leon et al. first reported 
high levels of CNA in patients with pancreatic cancer. 
In 2007 the use of CNA was proposed as a 
non-invasive tool for the early detection of cancer [23]. 
Recent studies have shown circulating RNA may be 
used as a valuable diagnostic tool for discriminating 
cancer patients from non-cancer individuals. Li et al. 
demonstrated that the mRNA profile was more 
complex in sera from oral squamous cell carcinoma 
patients than that in healthy controls using microarray 
and RT-PCR techniques [24]. Feng et al. found that the 
mean level of RNA in serum of patients with renal cell 
cancer was significantly higher than that in healthy 
individuals.[12] Here we demonstrated that USP36 
mRNA could be detected in 5/14 (36%) sera by 
RT-PCR from ovarian cancer patients. Additional 
studies are needed to validate these findings. 
In summary, using differential display, RT-PCR, 
and RNA in situ hybridization we confirmed the 
overexpression of USP36 in human ovarian cancer 
compared to normal ovaries. USP36 was detectable by 
RT-PCR in ovarian cancer tissue, ascites and serum 
specimens from ovarian cancer patients. Further work 
is necessary to identify the specific target of USP36 and 
to determine the role of this deubiquitinating enzyme 
in ovarian carcinogenesis or its prospect as a cancer 
biomarker.  
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